Abstract

BackgroundCorus CAD is a clinically validated test based on age, sex, and expression levels of 23 genes in whole blood that provides a score (1–40 points) proportional to the likelihood of obstructive coronary disease. Clinical laboratory process variability was examined using whole blood controls across a 24 month period: Intra-batch variability was assessed using sample replicates; inter-batch variability examined as a function of laboratory personnel, equipment, and reagent lots.Methods/ResultsTo assess intra-batch variability, five batches of 132 whole blood controls were processed; inter-batch variability was estimated using 895 whole blood control samples. ANOVA was used to examine inter-batch variability at 4 process steps: RNA extraction, cDNA synthesis, cDNA addition to assay plates, and qRT-PCR. Operator, machine, and reagent lots were assessed as variables for all stages if possible, for a total of 11 variables. Intra- and inter-batch variations were estimated to be 0.092 and 0.059 Cp units respectively (SD); total laboratory variation was estimated to be 0.11 Cp units (SD). In a regression model including all 11 laboratory variables, assay plate lot and cDNA kit lot contributed the most to variability (p = 0.045; 0.009 respectively). Overall, reagent lots for RNA extraction, cDNA synthesis, and qRT-PCR contributed the most to inter-batch variance (52.3%), followed by operators and machines (18.9% and 9.2% respectively), leaving 19.6% of the variance unexplained.ConclusionIntra-batch variability inherent to the PCR process contributed the most to the overall variability in the study while reagent lot showed the largest contribution to inter-batch variability.

Highlights

  • Peripheral blood gene expression profiling has been used to identify signatures which reflect a variety of pathological conditions, responses to pharmacological agents, and external environmental effects [1,2,3,4]

  • Intra-batch variability inherent to the PCR process contributed the most to the overall variability in the study while reagent lot showed the largest contribution to inter-batch variability

  • The process contains a number of quality control (QC) checkpoints and controls, including the whole blood control which is run with each batch of clinical samples (Fig. 1)

Read more

Summary

Introduction

Peripheral blood gene expression profiling has been used to identify signatures which reflect a variety of pathological conditions, responses to pharmacological agents, and external environmental effects [1,2,3,4]. It has been demonstrated that gene expression measurements can be affected by a number of ex-vivo events that start at the time of blood collection and continue, if care is not taken, during downstream processing [9,10,11]. An increasing number of peripheral blood gene expression signatures have been described, very few have yet been rigorously validated and implemented into broad clinical practice. We recently described the development and clinical validation of a peripheral blood gene expression test for the assessment of the likelihood of coronary artery disease in non-diabetic patients [8,12]. Corus CAD is a clinically validated test based on age, sex, and expression levels of 23 genes in whole blood that provides a score (1–40 points) proportional to the likelihood of obstructive coronary disease. Clinical laboratory process variability was examined using whole blood controls across a 24 month period: Intra-batch variability was assessed using sample replicates; inter-batch variability examined as a function of laboratory personnel, equipment, and reagent lots

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.